Literature DB >> 1759493

Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine.

C A Meitin1, B S Bender, P A Small.   

Abstract

To compare the efficacy and duration of the immune response to local and systemic vaccination, Balb/c mice were vaccinated either intraperitoneally (i.p.) with an inactivated A/PR/8/34 (H1N1) vaccine or intranasally (i.n.) with a vaccinia recombinant containing the H1 gene of influenza. The i.p. inactivated vaccine stimulated high serum IgG anti-influenza titres and protected the lungs against viral challenge for the duration of the experiment (17 months). Little nasal wash IgA was induced and the noses were susceptible to challenge. Animals vaccinated i.n. with the recombinant had lower serum IgG titres and the lungs showed poor protection against challenge. Nasal wash IgA titres were higher, however, and the noses were largely protected from viral challenge for 17 months.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759493     DOI: 10.1016/0264-410x(91)90292-e

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 2.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.

Authors:  S I Takao; K Kiyotani; T Sakaguchi; Y Fujii; M Seno; T Yoshida
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza.

Authors:  B S Bender; C A Rowe; S F Taylor; L S Wyatt; B Moss; P A Small
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Enteric immunization of mice against influenza with recombinant vaccinia.

Authors:  C A Meitin; B S Bender; P A Small
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

6.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method.

Authors:  Chad J Roy; Alida Ault; Satheesh K Sivasubramani; J Patrick Gorres; Chih-Jen Wei; Hanne Andersen; Jason Gall; Mario Roederer; Srinivas S Rao
Journal:  Respir Res       Date:  2011-11-21

8.  Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice.

Authors:  Hae-Jung Park; Boris Ferko; Young-Ho Byun; Joo-Hye Song; Gye-Yeong Han; Elisabeth Roethl; Andrej Egorov; Thomas Muster; Baiklin Seong; Mi-Na Kweon; Manki Song; Cecil Czerkinsky; Huan H Nguyen
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

9.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.